It is an oral steroidal aromatase inhibitor used in the adjuvant
treatment of hormonally-responsive breast cancer in
postmenopausal women. In this domain we have achieved a respectable position by offering our clients Exemestane. The drug acts as a false substrate for the aromatase
enzyme, and is processed to an intermediate, binds irreversibly to
the active site of the enzyme causing its inactivation. Exemestane converts hormones to estrogen in the body's adrenal glands. The drug educes estrogen levels by blocking the action of aromatase in the adrenal glands.